• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Y-mAbs Therapeutics Inc.

    5/30/25 4:13:09 PM ET
    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $YMAB alert in real time by email
    DEFA14A 1 ymab-20250530xdefa14a.htm DEFA14A

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of

    the Securities Exchange Act of 1934 (Amendment No. )

    ​

    ​

    Filed by the Registrant ⌧

    ​

    Filed by a Party other than the Registrant ◻

    ​

    Check the appropriate box:

    ◻

    Preliminary Proxy Statement

    ◻

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

    ◻

    Definitive Proxy Statement

    ⌧

    Definitive Additional Materials

    ◻

    Soliciting Material under §240.14a-12

    ​

    ​

    ​

    ​

    ​

    Y-MABS THERAPEUTICS, INC.

    (Name of Registrant as Specified In Its Charter)

    ​

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    ​

    Payment of Filing Fee (Check the appropriate box):

    ⌧

    No fee required.

    ◻

    Fee paid previously with preliminary materials.

    ◻

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

    ​

    ​


    GRAPHIC

    1. Election of Class I Director: David N. Gill 2. To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2025. 3. To approve, on a non-binding advisory vote basis, the compensation of the Company’s named executive officers as disclosed in the proxy statement. 4. To conduct any other business properly brought before the meeting or any adjournment or postponement thereof. THE BOARD RECOMMENDS A VOTE “FOR” THE ELECTION OF THE DIRECTOR NOMINEE, AND “FOR” ITEMS 2 AND 3. NOMINEE: This communication presents only an overview of the more complete proxy materials that are available to you on the Internet and is not a form for voting. We encourage you to access and review all of the important information contained in the proxy materials before voting. If you want to receive a paper or e-mail copy of the proxy materials you must request one. There is no charge to you for requesting a copy. If not requested, you will not receive a paper or e-mail copy of the proxy materials. To facilitate timely delivery please make the request as instructed below before 6/27/2025. Please visit http://www.astproxyportal.com/ast/22412, where the following materials are available for view: • Notice of Annual Meeting of Stockholders • Proxy Statement • Form of Electronic Proxy Card • Annual Report on Form 10-K TO REQUEST MATERIAL: TELEPHONE: 888-Proxy-NA (888-776-9962) or 201-299-6210 (for international callers) E-MAIL: [email protected] WEBSITE: https://us.astfinancial.com/OnlineProxyVoting/ProxyVoting/RequestMaterials TO VOTE: ONLINE: To access your online proxy card, please visit www.voteproxy.com and follow the on-screen instructions or scan the QR code with your smartphone. You may enter your voting instructions at www.voteproxy.com up until 11:59 PM Eastern Time the day before the cut-off or meeting date. VIRTUALLY AT THE MEETING: The company will be hosting the meeting live via the Internet this year. To attend the meeting via the Internet please visit https://meetings.lumiconnect.com/200-405-049-174 (password: ymabs2025) and be sure to have available the 11-digit control number listed above or in your electronic proxy card. TELEPHONE: To vote by telephone, please visit www.voteproxy.com to view the materials and to obtain the toll free number to call. MAIL: You may request a card by following the instructions above. COMPANY NUMBER ACCOUNT NUMBER CONTROL NUMBER JOHN SMITH 1234 MAIN STREET APT. 203 NEW YORK, NY 10038 Please note that you cannot use this notice to vote by mail. Important Notice Regarding the Availability of Proxy Materials for the Stockholder Meeting of Y-MABS THERAPEUTICS, INC. To Be Held On: July 11, 2025 at 8:00 a.m. Eastern Time For Stockholders of Record as of May 23, 2025 via the Internet at https://meetings.lumiconnect.com/200-405-049-174 (password: ymabs2025)

    Get the next $YMAB alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $YMAB

    DatePrice TargetRatingAnalyst
    4/22/2025$3.00Neutral → Underperform
    BofA Securities
    11/18/2024$23.00Outperform
    Oppenheimer
    8/16/2024$20.00Overweight
    Cantor Fitzgerald
    6/28/2024$21.00Buy
    Truist
    5/10/2023$5.00 → $13.00Neutral → Outperform
    Wedbush
    4/3/2023Buy → Neutral
    Guggenheim
    1/27/2023$4.00Equal-Weight → Underweight
    Morgan Stanley
    1/5/2023Outperform → Market Perform
    Cowen
    More analyst ratings

    $YMAB
    SEC Filings

    View All

    SEC Form SC 14D9 filed by Y-mAbs Therapeutics Inc.

    SC 14D9 - Y-mAbs Therapeutics, Inc. (0001722964) (Subject)

    8/18/25 9:24:22 AM ET
    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Y-mAbs Therapeutics Inc.

    SCHEDULE 13G - Y-mAbs Therapeutics, Inc. (0001722964) (Subject)

    8/15/25 4:28:04 PM ET
    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Y-mAbs Therapeutics Inc.

    SCHEDULE 13G - Y-mAbs Therapeutics, Inc. (0001722964) (Subject)

    8/12/25 4:16:22 PM ET
    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $YMAB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Y-mAbs Reports Second Quarter 2025 Financial Results and Recent Corporate Developments

    Reported Total Revenues of $19.5 million for the second quarter of 2025, exceeding the high end of the Company's guidance range of between $17 million and $19 millionSERB Pharmaceuticals to acquire Y-mAbs in $412.0 million transaction; transaction expected to close by the fourth quarter of 2025, subject to completion of tender offer and other customary conditionsAs of June 30, 2025, cash and cash equivalents were $62.3 millionIn light of the pending transaction, Y-mAbs will not be holding a webcast and conference call to discuss its second quarter 2025 results PRINCETON, N.J., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commer

    8/8/25 6:35:00 AM ET
    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Y-mAbs to Announce Second Quarter 2025 Financial and Operating Results on August 8, 2025

    PRINCETON, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of antibody-based therapeutics for the treatment of cancer, today announced it will report results for the second quarter 2025 before the market open on Friday, August 8, 2025. In light of the previously announced transaction with affiliated entities of SERB Pharmaceuticals, Y-mAbs will not be hosting an earnings conference call. About Y-mAbs Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, radioimmunotherapy and

    8/7/25 7:30:00 AM ET
    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SERB Pharmaceuticals Agrees to Acquire Y-mAbs Therapeutics

    Acquisition to Include Naxitamab-gqgk DANYELZA® (Naxitamab-gqgk), Further Broadening SERB's Rare Oncology Product Portfolio Transaction Expands SERB's Investment in the U.S. SERB to Commence All-Cash Tender Offer to Acquire All Outstanding Shares of Y-mAbs for $8.60 Per Share Represents 105% Premium to Y-mAbs Closing Share Price on August 4, 2025 WEST CONSHOHOCKEN, Pa. and PRINCETON, N.J., Aug. 05, 2025 (GLOBE NEWSWIRE) -- SERB Pharmaceuticals ("SERB"), a global specialty pharmaceutical company focused on medicines for rare diseases and medical emergencies, and Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) ("Y-mAbs" or "the Company"), a commercial-stage biopharmaceutical company focused on

    8/5/25 8:30:00 AM ET
    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $YMAB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Wg Biotech Aps bought $44,232 worth of shares (6,455 units at $6.85), increasing direct ownership by 0.14% to 4,559,233 units (SEC Form 4)

    4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)

    12/12/23 8:27:16 AM ET
    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wedell-Wedellsborg Johan bought $44,232 worth of shares (6,455 units at $6.85) (SEC Form 4)

    4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)

    12/12/23 8:26:25 AM ET
    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wg Biotech Aps bought $40,190 worth of shares (6,183 units at $6.50) and bought $850,222 worth of shares (121,366 units at $7.01), increasing direct ownership by 3% to 4,552,778 units (SEC Form 4)

    4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)

    12/11/23 5:25:50 PM ET
    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $YMAB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Tyagi Ashu was granted 25,080 shares, increasing direct ownership by 431% to 30,905 units (SEC Form 4)

    4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)

    7/2/25 4:20:24 PM ET
    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Hamill Laura was granted 25,080 shares, increasing direct ownership by 431% to 30,905 units (SEC Form 4)

    4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)

    7/2/25 4:20:27 PM ET
    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Wedell-Wedellsborg Johan was granted 25,080 shares, increasing direct ownership by 431% to 30,905 units (SEC Form 4)

    4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)

    7/2/25 4:20:21 PM ET
    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $YMAB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Y-mAbs Therapeutics downgraded by BofA Securities with a new price target

    BofA Securities downgraded Y-mAbs Therapeutics from Neutral to Underperform and set a new price target of $3.00

    4/22/25 7:23:34 AM ET
    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oppenheimer initiated coverage on Y-mAbs Therapeutics with a new price target

    Oppenheimer initiated coverage of Y-mAbs Therapeutics with a rating of Outperform and set a new price target of $23.00

    11/18/24 8:23:54 AM ET
    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald initiated coverage on Y-mAbs Therapeutics with a new price target

    Cantor Fitzgerald initiated coverage of Y-mAbs Therapeutics with a rating of Overweight and set a new price target of $20.00

    8/16/24 7:40:36 AM ET
    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $YMAB
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for DANYELZA issued to Y-MABS THERAPEUTICS INC

    Submission status for Y-MABS THERAPEUTICS INC's drug DANYELZA (SUPPL-8) with active ingredient NAXITAMAB-GQGK has changed to 'Approval' on 03/20/2024. Application Category: BLA, Application Number: 761171, Application Classification:

    3/21/24 10:20:07 AM ET
    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $YMAB
    Leadership Updates

    Live Leadership Updates

    View All

    Y-mAbs Appoints Experienced Commercial Leader as Head of DANYELZA Business Unit

    NEW YORK, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the appointment of Doug Gentilcore as Senior Vice President, Head of DANYELZA Business Unit. "I am pleased to welcome Doug to Y-mAbs as the new DANYELZA Business Unit head," said Michael Rossi, President and Chief Executive Officer. "We believe Doug's extensive experience leading pharmaceutical commercialization and operations on a global scale will be instrumental in our co

    1/10/25 7:35:00 AM ET
    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Y-mAbs Appoints Seasoned Biopharma Executive Peter Pfreundschuh as Chief Financial Officer

    NEW YORK, July 01, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the appointment of Peter Pfreundschuh as Chief Financial Officer, effective June 28, 2024. Mr. Pfreundschuh will report to Mike Rossi, President and Chief Executive Officer. "Y-mAbs is at a critical inflection point as we continue to gain U.S. commercial traction with DANYELZA® while simultaneously advancing the development of our differentiated Self-Assembly DisAssembly Pre

    7/1/24 4:05:00 PM ET
    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Y-mAbs Deepens Radiopharmaceutical Leadership with Appointment of Norman LaFrance, M.D. as Chief Development Officer

    NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the appointment of Norman LaFrance, M.D. as Chief Development Officer. "We are thrilled to welcome Dr. LaFrance to Y-mAbs," Mike Rossi, President and Chief Executive Officer. "Norman has an impressive track record in the research, development and commercialization of radiotherapeutics, molecular imaging, diagnostic and therapeutic products. With his deep expertise in develop

    6/5/24 7:05:00 AM ET
    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $YMAB
    Financials

    Live finance-specific insights

    View All

    Y-mAbs Reports Second Quarter 2025 Financial Results and Recent Corporate Developments

    Reported Total Revenues of $19.5 million for the second quarter of 2025, exceeding the high end of the Company's guidance range of between $17 million and $19 millionSERB Pharmaceuticals to acquire Y-mAbs in $412.0 million transaction; transaction expected to close by the fourth quarter of 2025, subject to completion of tender offer and other customary conditionsAs of June 30, 2025, cash and cash equivalents were $62.3 millionIn light of the pending transaction, Y-mAbs will not be holding a webcast and conference call to discuss its second quarter 2025 results PRINCETON, N.J., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commer

    8/8/25 6:35:00 AM ET
    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Y-mAbs to Announce Second Quarter 2025 Financial and Operating Results on August 8, 2025

    PRINCETON, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of antibody-based therapeutics for the treatment of cancer, today announced it will report results for the second quarter 2025 before the market open on Friday, August 8, 2025. In light of the previously announced transaction with affiliated entities of SERB Pharmaceuticals, Y-mAbs will not be hosting an earnings conference call. About Y-mAbs Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, radioimmunotherapy and

    8/7/25 7:30:00 AM ET
    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Y-mAbs Reports First Quarter 2025 Financial Results and Recent Corporate Developments

    Reported Net Product Revenues of $20.9 million for the first quarter of 2025, a year-over-year increase of approximately 8% National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Neuroblastoma updated to include naxitamab-gqgk (DANYELZA®)Dosed first patient in Phase 1 clinical trial evaluating CD38-SADA pretargeted radioimmunotherapy in patients with Relapsed/Refractory non-Hodgkin Lymphoma (Trial 1201)The Company to host virtual Radiopharmaceutical R&D update discussing Part A clinical data from its Phase I GD2-SADA clinical trial (Trial 1001) and announcing radioimmunotherapy and pipeline strategy on May 28, 2025As of March 31, 2025, cash and cash equiv

    5/13/25 6:35:00 AM ET
    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $YMAB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Y-mAbs Therapeutics Inc.

    SC 13G/A - Y-mAbs Therapeutics, Inc. (0001722964) (Subject)

    11/14/24 4:32:10 PM ET
    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Y-mAbs Therapeutics Inc.

    SC 13G/A - Y-mAbs Therapeutics, Inc. (0001722964) (Subject)

    11/12/24 6:00:40 PM ET
    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Y-mAbs Therapeutics Inc.

    SC 13G/A - Y-mAbs Therapeutics, Inc. (0001722964) (Subject)

    11/4/24 2:16:23 PM ET
    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care